2. Immunology/Inflammation
  3. CD276/B7-H3
  4. Omburtamab

Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

CAS No. : 1895083-75-6

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Omburtamab Featured Recommendations:

Omburtamab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC)[1][2].

Isotype

Human IgG1(K214R) kappa
Recommend Isotype Controls
Species

Human
In Vitro

Omburtamab (anti-B7-H3 mAb, 8H9) (100 nM; 24 h) significantly inhibits the viability of B7-H3-positive tumor cells (such as A549 and HCT116) and induces cell apoptosis in vitro, and can enhance natural killer cell-mediated tumor cell lysis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Omburtamab Related Antibodies

Cell Viability Assay[1]

Cell Line: A549, HCT 116, OVCAR-3, SK-OV-3, DLD-1, BT-474
Concentration: 100 nM
Incubation Time: 24 h
Result: Significantly reduced cell viability in B7-H3-positive tumor cell lines, with a dose-dependent decrease in metabolic activity compared to control groups.

Cell Cytotoxicity Assay[1]

Cell Line: A549, HCT 116, OVCAR-3, SK-OV-3, DLD-1, BT-474
Concentration: 100 nM
Incubation Time: 24 h
Result: Resulted a notable increase in apoptosis (Annexin V+/7-AAD+ cells) in A549 and HCT 116 cells, indicating caspase-dependent cell death induction.

Cell Cytotoxicity Assay[1]

Cell Line: A549, HCT 116, OVCAR-3, SK-OV-3, DLD-1, BT-474
Concentration: 100 nM
Incubation Time: 24 h
Result: Co-culture with peripheral blood mononuclear cells (PBMCs) revealed enhanced cytotoxicity against target cells, with specific lysis ratios increasing by 30–50% compared to untreated controls, mediated by CD16 signaling activation.
In Vivo

Omburtamab is derived into B7-H3 CAR and B7-H3/CD16 BiKE antibodies. B7-H3 CAR and B7-H3/CD16 BiKE (100 μg/mouse; intravenous injection; twice a week; a total of 4 times) significantly inhibit tumor growth and prolong mouse survival in NOD/SCID mouse subcutaneous transplantation non-small cell lung cancer (A549) and colorectal cancer (HCT 116) models without obvious systemic toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

144980.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Omburtamab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • IgG1-kappa
Purity & Documentation

Purity: 98.27%

SDS (251 KB)

COA (231 KB) SDS-PAGE (92 KB) SEC-HPLC (114 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Omburtamab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Omburtamab1895083-75-6CD276/B7-H3B7 homolog 3 proteintumor tissueInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Omburtamab
Cat. No.:
HY-P99157
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.